INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. The company is headquartered in Sarasota, Florida.
| Revenue (TTM) | $7.53M |
| Gross Profit (TTM) | $2.66M |
| EBITDA | $-5.37M |
| Operating Margin | -59.30% |
| Return on Equity | -55.30% |
| Return on Assets | -16.40% |
| Revenue/Share (TTM) | $7.17 |
| Book Value | $7.01 |
| Price-to-Book | 0.15 |
| Price-to-Sales (TTM) | 0.33 |
| EV/Revenue | 0.406 |
| EV/EBITDA | -1.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 16.70% |
| Shares Outstanding | $2.51M |
| Float | $2.28M |
| % Insiders | 0.90% |
| % Institutions | 16.89% |
Volatility is currently contracting
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET
SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that Gretchen Collins, M.D.
Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.
23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice relates to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "10-K"), and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "10-Q").
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced fiscal year 2025 financial results.
SARASOTA, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that on April 23, 2026, it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IVF and any ticker you trade — then tracks every position and per-strategy win rate.
